Commentary (Wong/Pritchard): Adjuvant Hormonal Therapy in Early Breast Cancer

Breast cancer is a systemic disease with 10-year relapse risks after surgery alone ranging between 30% and 50%.[1] About 60% to 75% of breast cancers are hormonereceptor– positive[2] and are potentially responsive to endocrine therapy, which remains a cornerstone in the adjuvant therapy of such tumors in this era of targeted therapy and genomics.